Please login to the form below

Revolade

This page shows the latest Revolade news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Promacta receives US breakthrough therapy designation

Known as Revolade in most countries outside the US, Promacta gained its breakthrough therapy designation following positive data, which 52% of treatment-naïve severe aplastic anaemia (SAA) patients achieved complete response ... Regulatory filings for a

Latest news

CHMP backs orphan drugs Uptravi and Coagadex

new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or
Novartis bags EU approvals for three ex-GSK drugs

Novartis bags EU approvals for three ex-GSK drugs. Revolade, Tafinlar and Mekinist all receive regulatory approval. ... The Swiss company announced this morning that platelet-boosting drug Revolade (eltrombopag) has become the first approved drug in the
EMA recommends two AbbVie treatments for hepatitis C

Over the last year, the EMA has recommended marketing authorisations for four new medicines for the treatment of HCV, including GSK's Revolade (eltrombopag) and Janssen's Olysio (simeprevir).
GSK files Promacta for anaemia indication in US

Outside the US, the drug is known as Revolade.
FDA deems GSK anaemia drug a 'breakthrough'

Outside the US, the drug is known as Revolade.

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Featured jobs

Project Manager, Medical Communications, Oxford: Excellent Salary

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Manager or AD - Medical Communications: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Medical Writer: Great salary and bebefits

Editor – Medical Education Agency – Bucks: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Programme Executive: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Scientific Director: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Medical Writer: Great salary and benefits

Senior Account Manager / Account Director: Great salary and bebefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Medical Writer, e-learning/ training, London: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...